Rights & Society
EMA Consults on Reducing Animal Use in Drug Development
The European Medicines Agency (EMA) is consulting on a new methodology using virtual control groups in preclinical research. This approach aims to reduce the number of animals used in medicines development. The draft qualification opinion from the CHMP provides a framework for companies. Stakeholders can provide feedback during the consultation period. This initiative aligns with the EU's commitment to animal welfare.
New EMA consultation seeks to reduce animal use in preclinical drug research.